Zenith Drugs IPO Day 1: Check subscription status, GMP and other details
₹40.68 crore from anchor investors from six anchor investors on February 16, by allocating 12,88,000 shares at ₹69 per share. Zenith Drugs Limited specialises in manufacturing and trading high-quality, affordable medicines, including generic drugs. Also read: Purv Flexipack IPO: Price band, issue size, GMP, key details to know Zenith Drugs Limited's revenue increased by 24.85 percent and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023.
The Zenith Drugs IPO was subscribed over 1.0 times on the first day of bidding. The SME IPO received 55,47,200 shares against offered 51,48,800 shares, as per data available on NSE. The retail category received 49,32,800 applications against offered 15,04,000.
Meanwhile, QIB section remained unsubscribed and NII received 6,14,400 applications against offered 6,44,800. Also read: Indian stock exchanges topped in number of IPOs in 2023: EY Report Zenith Drugs IPO is a book built issue of ₹40.68 crores. The issue is entirely a fresh issue of 51.49 lakh shares.
The price band of the SME IPO is set at ₹75 to ₹79 per share. Investors can bid for a minimum of 1600 shares and in multiples thereof. The minimum amount of investment required by retail investors is ₹126,400.
The minimum lot size investment for HNI is 2 lots (3,200 shares) amounting to ₹252,800. Zenith Drugs IPO offers 9,009,600 shares. 859,200 (9.54%) to QIB, 644,800 (7.16%) to NII, 1,504,000 (16.69%) to RII and 5,148,800 (57.15%) to Anchor investors.
Read more on livemint.com
